Immunomodulation and immunopharmacology in heart failure

Markousis-Mavrogenis, George; Baumhove, Lukas; Al-Mubarak, Ali A.; Aboumsallem, Joseph Pierre; Bomer, Nils; Voors, Adriaan A.; Van der Meer, Peter

doi:10.1038/s41569-023-00919-6

Record: found
Abstract: not found
Article: not found

Immunomodulation and immunopharmacology in heart failure

Author(s): George Markousis-Mavrogenis , Lukas Baumhove , Ali A. Al-Mubarak , Joseph Pierre Aboumsallem , Nils Bomer , Adriaan A. Voors , Peter van der Meer

Publication date (Electronic): September 14 2023

Journal: Nature Reviews Cardiology

Publisher: Springer Science and Business Media LLC

Read this article at

ScienceOpenPublisher

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 382

Record: found
Abstract: not found
Article: not found

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A McDonagh, Marco Metra, Marianna Adamo … (2021)

0 comments Cited 2640 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Paul M Ridker, Brendan M. Everett, Tom Thuren … (2017)

Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.

0 comments Cited 2106 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.